Open Access

Sustained choroid plexus function in human elderly and Alzheimer’s disease patients

Fluids and Barriers of the CNS201310:28

DOI: 10.1186/2045-8118-10-28

Received: 29 July 2013

Accepted: 18 September 2013

Published: 24 September 2013

Abstract

We and other investigators have postulated deterioration of essential choroid plexus (CP) functions in some elderly and especially Alzheimer’s disease patients based on apparent anatomical, histological and pathological changes in CP. We have termed this putative phenomenon CP failure. By focusing on four essential energy-requiring CP functions, specifically ascorbic acid (AA) and folate transport from blood into CSF, transthyretin synthesis and secretion into CSF, and electrolyte/acid–base balance in CSF, we were able to evaluate the hypothesis of CP failure by reviewing definitive human data. In both healthy elderly and Alzheimer’s disease patients, the CP functions normally to transport AA and folates actively from blood into CSF, synthesize and secrete transthyretin into CSF, and maintain CSF acid–base balance and ion concentrations. These human CSF compositional data provide no support for the notion of CP failure in elderly humans and Alzheimer’s disease patients.

Keywords

Ascorbic acid Folate Transthyretin Albumin Cerebrospinal fluid CSF acid–base balance CSF pH and bicarbonate CSF K homeostasis Methyltetrahydrofolate carrier Reduced folate carrier Na-K-Cl cotransporter Sodium vitamin C transporter 2 Choroidal epithelium Blood-CSF barrier CSF vitamins CSF formation rate

Introduction

The human choroid plexus (CP), a locus of the blood-CSF barrier (BCSFB), is an organ in the cerebral ventricles weighing approximately 2 grams[1]. The CP epithelium secretes most of the CSF and helps to maintain a stable extracellular environment for brain (homeostasis)[2]. The CP achieves these ends, in part, by clearing unwanted substances from the CSF[3, 4] and by pumping required compounds including certain vitamins [e.g., ascorbic acid (AA) and methyltetrahydrofolate (folates)], hormones and peptides from blood into CSF[2, 5]. From CSF, these substances penetrate into brain because there is a negligible barrier to penetration via diffusion at the CSF-brain interfaces[2, 6]. CP epithelial cells also synthesize peptides and proteins, e.g., transthyretin, for secretion into CSF[79].

In order to perform these functions, the human CP has an estimated blood flow of 4 to 5 ml/min/g and normally produces CSF at a rate of ~ 0.4 ml/minute, although there is substantial diurnal variation (see below)[2]. The anatomical BCSFB to even small molecules like urea[10] is due to the tight junctions that join the single-layered CP epithelial cells[2] in the ventricles and the multi-layered arachnoid membrane cells in the subarachnoid space. Capillaries in CP are “leaky”, unlike the microvessels in most of the brain where capillary endothelial cells are joined by tight junctions: the blood–brain barrier (BBB)[2].

Soon after our work on the vitamin transport systems in animal CP almost forty years ago, one of us (RS) and colleagues proposed that the non-stroke related dementias were due to a central vitamin deficiency state secondary to CP failure–analogous to renal failure[11]. This hypothesis was based on the anatomical and structural changes in CP of the elderly, and especially, in demented patients[1]. How could such a severely damaged CP organ perform adequately in Alzheimer’s disease? Subsequently others refined and expanded this failing CP hypothesis[12, 13], including considerations for aging animal models[14, 15]. However, we now summarize human data demonstrating, in both the elderly and Alzheimer’s patients, that this hypothesis needs reconsideration. It is important to resolve such hypotheses so that more fruitful avenues of research can be pursued.

Interpretation of the human data

In order to evaluate CP function in the elderly and Alzheimer’s disease patients, we focus on four essential functions of the CP–AA and folate transport from blood into CSF via the CP, transthyretin synthesis/secretion into CSF[14], and CSF ion and pH homeostasis[2, 16]. If these four diverse CP-CSF functions are maintained in human elderly and Alzheimer’s patients, since there are no known alternative compensating mechanisms at the BCSFB, such data would strongly intimate that the fundamental CP transporters are functioning normally. Before reviewing the human data, a brief overview of these transport systems and comments on CSF production will put the human data in better perspective.

AA transport into brain via CP

Hammarstrom, based on elegant autoradiographic studies of 14C-ascorbate distribution in mice, first proposed that AA was transported into CSF, and then brain, via the CP[6, 17, 18]. We confirmed and extended this hypothesis in rabbits[6, 17, 18]. AA does not enter brain directly through the capillaries of the BBB. In humans, there is also strong evidence for CNS penetration via CP-CSF rather than brain capillaries[18]. Subsequent work showed that the key AA transport system in CP is the sodium-dependent vitamin C transport system (SVCT2). SVCT2 is present on the basal (blood) side of the CP epithelium and neurons[19]. In vivo, in mammals including humans, the CP efficiently pumps AA from the blood flowing through the CP into CSF with a step-up in concentration of ~ 4 times[1719]. In neurons AA is concentrated by another factor of ~50 by SVCT2 in the neuronal plasma membrane[19]. Thus, the concentration of AA in human plasma, CSF and brain neurons is ~ 50, 200, and 10,000 μM; and in whole brain the concentration approaches several mM[19]. The KT (one-half saturation concentration) for SVCT2 is ~50 μM[18, 19]. The correctness of this model is corroborated by the phenotype of SVCT2 knock-out (KO) mice and by the finding of multiple investigators that there is no SVCT2 protein in brain capillaries[19].

For details of the AA system in CP, there are many excellent reviews[1921]. Still unknown is how AA exits the CP into CSF. But what is clear is how this elegant system maintains AA homeostasis in the central nervous system[6, 18]. At low plasma concentrations, relatively more AA is pumped into CSF via the CP; at high concentrations, relatively less. In guinea pigs (which like humans cannot synthesize AA), the brain is the last organ to be depleted of AA in an experimentally-induced dietary AA deficiency state[6].

Folate transport into CSF via CP

The folate transport system in CP works similarly to the AA system, actively pumping methyltetrahydrofolate, the principal folate in plasma, into CSF. Consequently, the steady-state concentration of methyltetrahydrofolate in CSF is ~2-4 times that of plasma[2, 19, 20]. The CP mechanism that transports folate from blood into CSF requires, in sequence, the folate receptor α (FRα) on the basal side of CP, the proton-coupled folate transporter (PCFT; SLC 46A1) and probably the reduced folate carrier (RFC; SLC 19 A1) at the apical side of CP[19, 20]. There is evidently no FRα or PCFT in brain capillaries[19, 20]. Naturally-occurring human KO’s of either FRα or PCFT lead to central folate deficiency states, very low CSF folate concentrations and severe neurological disease or death, establishing beyond doubt (in humans) the role of the CP in pumping folates from blood into CSF. From CSF, folates are transported into brain[19, 20]. However, the exact mechanism(s) by which folates in CSF are transferred from human CSF into brain awaits elucidation. One group has postulated vesicular transport of folates out of mammalian CP through CSF and into brain[22]. However, in rabbits, over 70% of the CSF folate transferred from blood into CSF is present as free methyltetrahydrofolate not bound in vesicles[23]. We think that non-vesicular CSF folate transport occurs in humans since otherwise it would not be possible to measure CSF folate by current methods were it mainly bound in vesicles. However, the proportion of vesicular (if any) vs. non-vesicular transport of folate via human CSF remains to be experimentally determined.

Transthyretin synthesis and secretion by CP

Transthyretin (TTR) is a protein of 508 amino acids[7]. Although the CSF protein level is < 1% that of plasma, approximately 10% of CSF protein is TTR[2, 7]. Greater than 90% of the TTR in CSF is synthesized within and secreted into CSF by the CP[7]. Fasting reduces serum TTR (synthesized in liver) while the CSF concentration remains stable[7].

Ion transport and acid–base balance in CSF

Another major function of CP epithelial cells is to maintain the Na, K and H ion concentrations in CSF[2, 9, 24]. Choroidal transport proteins, such as the CSF-facing Na-K pump and the Na-K-Cl cotransporter[25], actively maintain CSF [K+] close to 2.9 mM (or mEq/L) and [Na+] about 150 mM. Acid–base transporters in the BCSFB stabilize CSF pH near 7.3[9] and [HCO3-] at about 24 mM. Perturbations in plasma electrolytes are not mirrored in CSF due to: i) the diffusion restriction imposed by the BCSFB tight junctions and, ii) the transporter activity by CP epithelium that tightly controls ion concentrations in secreted CSF[9, 26, 27].

CSF production rates in the elderly and Alzheimer’s patients

Because reduced CSF production could alter solute concentrations in CSF, we reviewed the extant data on CSF formation in the elderly and Alzheimer’s patients. In the elderly, several studies have measured CSF production rates compared to younger humans. In seven normal elderly and seven young adults, May et al. employed the invasive Masserman technique which involves withdrawing CSF and then waiting for CSF baseline pressure to be restored[28]. By this indirect approach, May et al. reported decreased CSF production in the elderly[28]. However, there are several issues with this un-validated, fluid removal technique in humans (see below). Alternatively and more recently, a small, non-invasive phase-mapping study by MRI found no difference in CSF production in the young versus elderly[29]. In another investigation, Nilsson et al. quantified a >2-fold diurnal variation in human CSF production employing MRI analysis[30]. Therefore due to variability in methodology and findings, we conclude that the human CSF production rate as a function of age requires further examination.

In a study comparing CSF production in 7 patients with Alzheimer’s disease versus Parkinson’s patients, Silverberg et al. reported that CSF production was substantially decreased in Alzheimer’s patients[31]. However, they used a modification of the un-validated Masserman technique withdrawing 3 ml of ventricular CSF. Moreover, the Alzheimer’s patients were subject to general anesthesia; the “control” Parkinson’s patients, “conscious sedation.” Anesthesia has marked effects on CSF pressure and production rates[2]. Therefore the CSF dynamics data generated by the Masserman approach are not definitive. In the description below on CSF composition in the elderly and Alzheimer’s patients, we offer indirect evidence that the CSF production rate in dementia patients is normal or near normal. This may bear on interpreting CSF solute concentrations. Even if CSF formation rate remains stable, however, there might be a slower CSF turnover rate in aging or dementia if CSF volume is significantly increased[9]. A reduced CSF turnover rate[15, 32, 33] could affect CSF concentration of passively-distributed substances (such as albumin) between blood and CSF[34], but awaiting elucidation is how altered turnover rate would affect (if at all) the level of substances actively distributed by carrier mechanisms in CP.

AA in CSF and brain of elderly and Alzheimer’s patients

In a superb study using a validated, non-invasive technique with magnetic resonance spectroscopy (MRS), Emir et al. showed that in the elderly (mean age 76; N = 22) the AA concentration in occipital cortex was slightly higher than in young adults (mean age 20; N = 22)[35]. This MRS finding is consistent with an ample supply of AA to neurons from the CP-CSF nexus.

Three age-and sex-matched, controlled studies of CSF and plasma AA levels in Alzheimer’s patients were described in an excellent review by Bowman[36]. The mean data from all three AA investigations are summarized in Table 1. What is remarkable (Table 1) is that although the CSF AA concentration was 13% lower in the Alzheimer’s patients, the mean ratio of CSF/plasma AA was 33% higher. This is expected of such ratios if the CP active and carrier-mediated transport is functioning normally; by Michaelis-Menten transport kinetics as the plasma concentration declines, relatively more AA is pumped into the ventricles to maintain CSF (and secondarily brain) homeostasis. As noted in Table 1, the mean plasma concentration in the Alzheimer’s patients was 31% lower than in age and sex-matched controls, presumably due to less AA in their dietary intake. In a separate uncontrolled study of 32 Alzheimer’s patients, Bowman et al. found a mean CSF/plasma ratio of 4.0 ± 0.3 (SEM)– confirming the findings summarized in Table 1[37]. Collectively, these data provide no support for abnormal AA transport function in CP of elderly or Alzheimer’s patients. In fact, they strongly support the normal ability of CP in Alzheimer’s patients to actively concentrate AA in CSF.
Table 1

Mean plasma and CSF AA concentrations, and ratios of CSF/plasma AA concentrations in Alzheimer’s patients and controls*

Assessment

Control

Alzheimer’s

CSF AA (μM)

183

160

(N)

(43)

(47)

Plasma AA (μM)

68

47

(N)

(43)

(47)

Ratio of AA, CSF/plasma

3.0

4.0

(N)

(43)

(47)

*The data are weighted means of three age-and sex-matched, controlled studies (See Table 3 of Bowman[36] for details.) Number of subjects is in parentheses.

CSF folate concentration in elderly and Alzheimer’s patients

In 36 elderly men and women (mean age 73), Serot et al. found no difference in the mean concentration of CSF folate versus that in 60 younger adults (mean age 40)[38]. However, in 36 Alzheimer’s patients, Serot reported a 17% mean decrease in CSF folate and an 8% mean decrease in plasma folate compared with the 36 elderly controls[38]. Although the CSF concentration of folate in Alzheimer’s patients was slightly lower than in aged controls, it was still within the normal range and not low enough to cause symptoms. Moreover, the CSF folate concentration in Alzheimer’s patients was still much higher than the plasma concentration. This reflects adequate CP functioning, i.e., maintenance of CSF folate against an uphill concentration gradient across the BCSFB. Others[39] have reported normal CSF folate concentrations in Alzheimer’s patients and showed, as expected, a negative correlation between the plasma folate concentration and the ratio of CSF/plasma folate (P 0.001). This confirms the normal, saturable operation of the folate transport system in CP in Alzheimer’s disease[19, 20, 23].

CSF transthyretin in the elderly and Alzheimer’s patients

In lumbar CSF of patients with a normal level of CSF protein and less than three cells/ml of CSF, Serot et al. measured TTR[7]. As per Table 2, Alzheimer’s patients had a mean 13% decrease in CSF [TTR] vs. elderly controls, but a CSF TTR level comparable to middle-aged controls and higher than in young subjects. It is risky to interpret these data too finely, but clearly Alzheimer’s patients have a CSF TTR concentration within the normal range. This strongly implies adequate CP secretory function.
Table 2

Transthyretin (TTR) concentration in lumbar CSF*

Group (mean age)

Mean TTR (mg/L) ± SD (N)

% control

Age-matched controls (76)

20.0 ± 2.5 (41)

 

Alzheimer’s patients (74)

17.5 ± 2.0 (40)

87

Middle-aged (41)

17.4 ± 2.4 (51)

87

Youth (10)

15.5 ± 1.8 (17)

78

*Data are compiled from Serot et al.[7].

Moreover, Serot et al. also measured CSF albumin in these subjects[7]. The mean concentrations of CSF albumin in the middle-aged controls (N = 51), elderly (N = 41) and Alzheimer’s patients (N = 40) were 0.21, 0.22, and 0.22 g/L, respectively. These similar CSF albumin concentration data fit the notion that there is no appreciable loss of integrity of the blood-CSF barrier with aging and Alzheimer’s disease. This conclusion seems likely because increased CP permeability in dementia would presumably have caused an increased concentration of CSF albumin. Moreover, deductively, there is probably no substantial decrement in CSF production since a lower fluid turnover rate would also tend to increase the CSF albumin concentration. Others have reported CSF albumin concentration stability in Alzheimer’s disease[39].

Stability of CSF electrolytes and pH in Alzheimer’s disease

In Alzheimer’s subjects, there is compelling evidence for unaltered concentrations of CSF [Na+] and [K+] compared to young subjects and age-matched controls[40] (Table 3). This is in line with the upregulated Na-K-Cl cotransporter protein in human CP in Alzheimer’s disease[9, 13]; this apically-located cotransporter, along with the Na-K exchange pump, has a putative role in CSF inorganic ion homeostasis by adjusting ion fluxes across the CSF-facing membrane of choroid epithelium[25]. Similarly, Alzheimer’s patients had normal CSF acid–base balance (pH = 7.33) and pCO2 levels[41, 42] (Table 3). Such CSF acid–base stability in the elderly and Alzheimer’s subjects points to compensatory functioning of HCO3- and H+ transporters at the BCSFB. Accordingly, although the information is somewhat limited, the available evidence (CSF ion composition data from 30 Alzheimer’s patients and 50 control or normal subjects) strongly suggests that regulatory Na+, K+ and H+/HCO3- transport at the BCSFB is maintained in Alzheimer’s disease[4042].
Table 3

[Na + ], [K + ], [HCO 3 ], pH and pCO 2 in CSF of normals, controls and Alzheimer’s patients*

Ion**

Normal values

Controls

Alzheimer’s

[Na+]

------

146 ± 2 (15)

147 ± 2 (15)

[K+]

------

2.8 ± 0.1 (15)

2.8 ± 0.1 (15)

[HCO3-]

22.9 ± 2.3 (35)

------

23.4 ± 1.3 (15)

pH

7.31 ± 0.03 (35)

------

7.33 ± 0.03 (15)

pCO2 (mm Hg)

47.9 ± 5.7 (35)

------

46.9 ± 3.2 (15)

Normals = normal adults; controls = age-and sex-matched elderly.

*[Na] and [K] data are compiled from Vitvitsky et al.[40]. Acid–base data are obtained from Posner et al.[42] (normal values) and Gottfries et al.[41] (controls and Alzheimer’s patients).

** Ion concentrations are in mEq/L.

≠ All values are means ± SD; N = number of subjects in parentheses.

Discussion and conclusion

The collective observations for CP-CSF function in four different complex energy-requiring transport and homeostatic systems (AA and folate transport into CSF via CP, TTR synthesis/secretion into CSF by CP, and impressive ion and pH stability in CSF) strongly support the notion that the CP in elderly and Alzheimer’s patients generally functions well. This is in the face of clear histological, pathological and anatomical modifications in CP tissue of some elderly and Alzheimer’s disease patients[1, 12, 13, 31]. Thus, the hypothesis of compromised CP homeostatic transport failure in some elderly and Alzheimer’s patients, postulated earlier by us and others[1113], is not supported by the CSF compositional evidence reported in this review. Clearly there is more work to be done such as resolving CSF production rates using validated techniques taking diurnal variation, anesthesia and other factors into account. However, the human CSF data reported herein by us and others substantiate the maintenance of CP transport and homeostatic functions in the elderly and Alzheimer’s disease.

Abbreviations

AA: 

Ascorbic acid

Alz’s: 

Alzheimer’s disease

BBB: 

Blood–brain barrier

BCSFB: 

Blood-CSF barrier

CP: 

Choroid plexus

CSF: 

Cerebrospinal fluid

KO: 

Knock out

Na-K-Cl cotransporter: 

Sodium-potassium-chloride cotransporter in CP

PCFT: 

Proton-coupled folate transporter

RFC: 

Reduced folate carrier

SVCT2: 

Sodium-dependent vitamin C transporter 2

TTR: 

Transthyretin.

Declarations

Acknowledgement

The authors thank Michiko Spector and Nancy Johanson for their aid in the preparation of this manuscript.

Authors’ Affiliations

(1)
Department of Medicine, Robert Wood Johnson Medical School
(2)
Department of Neurosurgery, Alpert Medical School at Brown University

References

  1. Netsky M, Shuangshoti S: The choroid plexus in health and disease. 1975, Charlottesville: University Press of Virginia
  2. Davson H, Welch K, Segal M: The physiology and pathophysiology of the cerebrospinal fluid. 1987, New York: Churchill Livingstone
  3. Miller DS: Confocal imaging of xenobiotic transport across the choroid plexus. Adv Drug Deliv Rev. 2004, 56: 1811-1824. 10.1016/j.addr.2004.07.010.PubMedView Article
  4. Spector R: Nature and consequences of mammalian brain and CSF efflux transporters: four decades of progress. J Neurochem. 2010, 112: 13-23. 10.1111/j.1471-4159.2009.06451.x.PubMedView Article
  5. Smith DE, Johanson CE, Keep RF: Peptide and peptide analog transport systems at the blood-CSF barrier. Adv Drug Deliv Rev. 2004, 56: 1765-1791. 10.1016/j.addr.2004.07.008.PubMedView Article
  6. Spector R: Penetration of ascorbic acid from cerebrospinal fluid into brain. Exp Neurol. 1981, 72: 645-653. 10.1016/0014-4886(81)90013-3.PubMedView Article
  7. Serot JM, Christmann D, Dubost T, Couturier M: Cerebrospinal fluid transthyretin: aging and late onset Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1997, 63: 506-508. 10.1136/jnnp.63.4.506.PubMed CentralPubMedView Article
  8. Chen RL, Athauda SB, Kassem NA, Zhang Y, Segal MB, Preston JE: Decrease of transthyretin synthesis at the blood-cerebrospinal fluid barrier of old sheep. J Gerontol A Biol Sci Med Sci. 2005, 60: 852-858. 10.1093/gerona/60.7.852.PubMedView Article
  9. Johanson CE, Duncan JA, Klinge PM, Brinker T, Stopa EG, Silverberg GD: Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res. 2008, 5: 10-10.1186/1743-8454-5-10.PubMed CentralPubMedView Article
  10. Johanson CE, Woodbury DM: Uptake of [14C]urea by the in vivo choroid plexus–cerebrospinal fluid–brain system: identification of sites of molecular sieving. J Physiol. 1978, 275: 167-176.PubMed CentralPubMedView Article
  11. Spector R, Cancilla P, Damasio A: Is idiopathic dementia a regional vitamin deficiency state?. Med Hypotheses. 1979, 5: 763-767. 10.1016/0306-9877(79)90038-0.PubMedView Article
  12. Rubenstein E: Relationship of senescence of cerebrospinal fluid circulatory system to dementias of the aged. Lancet. 1998, 351: 283-285. 10.1016/S0140-6736(97)09234-9.PubMedView Article
  13. Johanson C, McMillan P, Tavares R, Spangenberger A, Duncan J, Silverberg G, Stopa E: Homeostatic capabilities of the choroid plexus epithelium in Alzheimer’s disease. Cerebrospinal Fluid Res. 2004, 1: 3-10.1186/1743-8454-1-3.PubMed CentralPubMedView Article
  14. Redzic ZB, Preston JE, Duncan JA, Chodobski A, Szmydynger-Chodobska J: The choroid plexus-cerebrospinal fluid system: from development to aging. Curr Top Dev Biol. 2005, 71: 1-52.PubMedView Article
  15. Preston JE: Ageing choroid plexus-cerebrospinal fluid system. Microsc Res Tech. 2001, 52: 31-37. 10.1002/1097-0029(20010101)52:1<31::AID-JEMT5>3.0.CO;2-T.PubMedView Article
  16. Johanson C: Choroid plexus-CSF circulatory dynamics: impact on brain growth, metabolism and repair. Neuroscience in Medicine. Edited by: Conn P. 2008, Totowa, New Jersey: The Humana Press, 173-200.View Article
  17. Spector R, Lorenzo AV: Specificity of ascorbic acid transport system of the central nervous system. Am J Physiol. 1974, 226: 1468-1473.PubMed
  18. Spector R, Lorenzo AV: Ascorbic acid homeostasis in the central nervous system. Am J Physiol. 1973, 225: 757-763.PubMed
  19. Spector R: Nutrient transport systems in brain: 40 years of progress. J Neurochem. 2009, 111: 315-320. 10.1111/j.1471-4159.2009.06326.x.PubMedView Article
  20. Spector R, Johanson CE: Vectorial ligand transport through mammalian choroid plexus. Pharm Res. 2010, 27: 2054-2062. 10.1007/s11095-010-0162-2.PubMedView Article
  21. Harrison FE, May JM: Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. Free Radic Biol Med. 2009, 46: 719-730. 10.1016/j.freeradbiomed.2008.12.018.PubMed CentralPubMedView Article
  22. Grapp M, Wrede A, Schweizer M, Huwel S, Galla HJ, Snaidero N, Simons M, Buckers J, Low PS, Urlaub H: Choroid plexus transcytosis and exosome shuttling deliver folate into brain parenchyma. Nat Commun. 2013, 4: 2123-PubMedView Article
  23. Spector R, Lorenzo AV: Folate transport in the central nervous system. Am J Physiol. 1975, 229: 777-782.PubMed
  24. Nattie EE: Ionic mechanisms of cerebrospinal fluid acid–base regulation. J Appl Physiol. 1983, 54: 3-12.PubMed
  25. Keep RF, Xiang J, Betz AL: Potassium cotransport at the rat choroid plexus. Am J Physiol. 1994, 267: C1616-C1622.PubMed
  26. Parmelee JT, Bairamian D, Johanson CE: Response of infant and adult rat choroid plexus potassium transporters to increased extracellular potassium. Brain Res Dev Brain Res. 1991, 60: 229-233. 10.1016/0165-3806(91)90051-J.PubMedView Article
  27. Husted RF, Reed DJ: Regulation of cerebrospinal fluid bicarbonate by the cat choroid plexus. J Physiol. 1977, 267: 411-428.PubMed CentralPubMedView Article
  28. May C, Kaye JA, Atack JR, Schapiro MB, Friedland RP, Rapoport SI: Cerebrospinal fluid production is reduced in healthy aging. Neurology. 1990, 40: 500-503. 10.1212/WNL.40.3_Part_1.500.PubMedView Article
  29. Gideon P, Thomsen C, Stahlberg F, Henriksen O: Cerebrospinal fluid production and dynamics in normal aging: a MRI phase-mapping study. Acta Neurol Scand. 1994, 89: 362-366.PubMedView Article
  30. Nilsson C, Stahlberg F, Thomsen C, Henriksen O, Herning M, Owman C: Circadian variation in human cerebrospinal fluid production measured by magnetic resonance imaging. Am J Physiol. 1992, 262: R20-R24.PubMed
  31. Silverberg GD, Heit G, Huhn S, Jaffe RA, Chang SD, Bronte-Stewart H, Rubenstein E, Possin K, Saul TA: The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer’s type. Neurology. 2001, 57: 1763-1766. 10.1212/WNL.57.10.1763.PubMedView Article
  32. Chen RL, Kassem NA, Redzic ZB, Chen CP, Segal MB, Preston JE: Age-related changes in choroid plexus and blood-cerebrospinal fluid barrier function in the sheep. Exp Gerontol. 2009, 44: 289-296. 10.1016/j.exger.2008.12.004.PubMedView Article
  33. Chiu C, Miller MC, Caralopoulos IN, Worden MS, Brinker T, Gordon ZN, Johanson CE, Silverberg GD: Temporal course of cerebrospinal fluid dynamics and amyloid accumulation in the aging rat brain from three to thirty months. Fluids Barriers CNS. 2012, 9: 3-10.1186/2045-8118-9-3.PubMed CentralPubMedView Article
  34. Chen RL, Chen CP, Preston JE: Elevation of CSF albumin in old sheep: relations to CSF turnover and albumin extraction at blood-CSF barrier. J Neurochem. 2010, 113: 1230-1239.PubMed
  35. Emir UE, Raatz S, McPherson S, Hodges JS, Torkelson C, Tawfik P, White T, Terpstra M: Noninvasive quantification of ascorbate and glutathione concentration in the elderly human brain. NMR Biomed. 2011, 24: 888-894. 10.1002/nbm.1646.PubMed CentralPubMedView Article
  36. Bowman GL: Ascorbic acid, cognitive function, and Alzheimer’s disease: a current review and future direction. Biofactors. 2012, 38: 114-122. 10.1002/biof.1002.PubMed CentralPubMedView Article
  37. Bowman GL, Dodge H, Frei B, Calabrese C, Oken BS, Kaye JA, Quinn JF: Ascorbic acid and rates of cognitive decline in Alzheimer’s disease. J Alzheimers Dis. 2009, 16: 93-98.PubMed CentralPubMed
  38. Serot JM, Christmann D, Dubost T, Bene MC, Faure GC: CSF-folate levels are decreased in late-onset AD patients. J Neural Transm. 2001, 108: 93-99. 10.1007/s007020170100.PubMedView Article
  39. Hagnelius NO, Wahlund LO, Nilsson TK: CSF/serum folate gradient: physiology and determinants with special reference to dementia. Dement Geriatr Cogn Disord. 2008, 25: 516-523. 10.1159/000129696.PubMedView Article
  40. Vitvitsky VM, Garg SK, Keep RF, Albin RL, Banerjee R: Na + and K + ion imbalances in Alzheimer’s disease. Biochim Biophys Acta. 1822, 2012: 1671-1681.
  41. Gottfries CG, Kjallquist A, Ponten U, Roos BE, Sundbarg G: Cerebrospinal fluid pH and monoamine and glucolytic metabolites in Alzheimer’s disease. Br J Psychiatry. 1974, 124: 280-287. 10.1192/bjp.124.3.280.PubMedView Article
  42. Posner JB, Swanson AG, Plum F: Acid–base balance in cerebrospinal fluid. Arch Neurol. 1965, 12: 479-496. 10.1001/archneur.1965.00460290035006.PubMedView Article

Copyright

© Spector and Johanson; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement